IMPROving MYelin imaging in patients with relapsing-remitting multiple sclerosis (IMPROMYMS study): protocol for a prospective longitudinal study

INTRODUCTION: It is increasingly recognized that patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression in the absence of clinical relapses and new lesions, a phenomenon known as progression independent of relapse- and magnetic resonance imaging (MRI) activity (PIRMA). The biological basis of this type of progression remains poorly understood. Demyelination is the central pathological hallmark of RRMS. Conventional clinical MRI protocols focus primarily on detecting focal lesions. However, advanced imaging techniques that quantify myelin content can provide additional insights beyond visible lesions, helping to better understand the mechanisms that drive clinical deterioration. OBJECTIVE: Therefore, this study named IMPROving MYelin imaging in patients with relapsing-remitting Multiple Sclerosis (IMPROMYMS study) aims to apply myelin imaging techniques to study clinically defined disease progression in patients with RRMS, by assessing myelin content and comparing it to patients with RRMS without progression of the disease. METHODS: In total, 97 patients with RRMS will be included and followed for 2.5 years. Participants will undergo MRI scanning at baseline and after 2 years and have regular clinical follow-up visits. Besides conventional MRI, advanced imaging sequences will be scanned, including gradient spin echo (GRASE), multi-echo gradient echo (ME-GRE), diffusion and functional MRI. Additionally, blood samples will be collected longitudinally to assess circulating biomarkers of neuroaxonal damage and astrocytic activation. Participants can also use the smartphone symptom-monitoring app MS Sherpa to enable more frequent monitoring of functional changes in daily life. In addition, 30 healthy controls will be scanned once as a reference group. In this study, we expect to find radiological prognostic markers of an increased risk of developing PIRMA, so that disease management strategies can be altered accordingly.

Authors

Institutions

Publication Details

Journal
Neuroradiology
Published
2026-11-16
DOI
https://doi.org/10.1007/s00234-026-04221-3
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

IMPROving MYelin imaging in patients with relapsing-remitting multiple sclerosis (IMPROMYMS study): protocol for a prospective longitudinal study

Svitlana Zinger, Jacobus F.A. Jansen, Simone Monachino, Gerhard S. Drenthen et al.
2 links
Neuroradiology
Multiple Sclerosis Research Studies
article

IMPROving MYelin imaging in patients with relapsing-remitting multiple sclerosis (IMPROMYMS study): protocol for a prospective longitudinal study

Svitlana Zinger, Jacobus F.A. Jansen, Simone Monachino, Gerhard S. Drenthen, Marcel M. Breeuwer, Stephanie A. M. Knippenberg, Catarina Dinis Fernandes, Oliver H.H. Gerlach, Lis J M van den Boogaard
article en

Abstract

INTRODUCTION: It is increasingly recognized that patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression in the absence of clinical relapses and new lesions, a phenomenon known as progression independent of relapse- and magnetic resonance imaging (MRI) activity (PIRMA). The biological basis of this type of progression remains poorly understood. Demyelination is the central pathological hallmark of RRMS. Conventional clinical MRI protocols focus primarily on detecting focal lesions. However, advanced imaging techniques that quantify myelin content can provide additional insights beyond visible lesions, helping to better understand the mechanisms that drive clinical deterioration. OBJECTIVE: Therefore, this study named IMPROving MYelin imaging in patients with relapsing-remitting Multiple Sclerosis (IMPROMYMS study) aims to apply myelin imaging techniques to study clinically defined disease progression in patients with RRMS, by assessing myelin content and comparing it to patients with RRMS without progression of the disease. METHODS: In total, 97 patients with RRMS will be included and followed for 2.5 years. Participants will undergo MRI scanning at baseline and after 2 years and have regular clinical follow-up visits. Besides conventional MRI, advanced imaging sequences will be scanned, including gradient spin echo (GRASE), multi-echo gradient echo (ME-GRE), diffusion and functional MRI. Additionally, blood samples will be collected longitudinally to assess circulating biomarkers of neuroaxonal damage and astrocytic activation. Participants can also use the smartphone symptom-monitoring app MS Sherpa to enable more frequent monitoring of functional changes in daily life. In addition, 30 healthy controls will be scanned once as a reference group. In this study, we expect to find radiological prognostic markers of an increased risk of developing PIRMA, so that disease management strategies can be altered accordingly.

Neuroradiology
Maastricht University Medical Centre (NL), Maastricht University (NL), Kempenhaeghe (NL), Zuyderland Medisch Centrum (NL), Eindhoven University of Technology (NL)
Health~Holland, Hersenstichting
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon